<DOC>
	<DOCNO>NCT02665026</DOCNO>
	<brief_summary>The purpose study evaluate appropriate timing preventive ileostomy closure total mesorectal excision rectal cancer . To evaluate effectiveness safety preventive ileostomy closure different time ( 12 week / 24 week radical resection rectal carcinoma ) . This study expect demonstrate early preventive ileostomy closure total mesorectal excision rectal cancer increase risk complication .</brief_summary>
	<brief_title>Effectiveness Safety Study Different Timing Preventive Ileostomy Closure After Surgery Rectal Cancer</brief_title>
	<detailed_description>A temporary stoma may , fact , result reduce quality life feeling physical mental restriction , debilitate nuisance , among problem . Skin irritation , prolapse , retractionare quite common ileostomy . A high incidence parastomal hernia , ileus , increase salt fluid loss report , may also contribute great willingness surgeon patient close temporary stoma soon possible . Currently , remain unclear whether stoma closure perform end chemotherapy chemotherapy ( 12 week 24 week radical resection rectal carcinoma ) . The aim study ass possible impact stoma closure time postoperative result evaluate early preventive ileostomy closure total mesorectal excision rectal cancer increase risk complication .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>sign inform consent postoperative pathology rectal adenocarcinoma primary middle low rectal cancer patient ( tumor distance anal margin le 10 cm ) underwent total mesorectal excision rectal cancer preventive loop ileostomy postoperative pathology rectal adenocarcinoma ( rectal neuroendocrine tumor , lymphoma , etc . ) postoperative pathologic stag rectal cancer I phase , II phase underwent total mesorectal excision rectal cancer without preventive loop ileostomy emergency operation rectal cancer disease progression ( local recurrence distant metastasis , etc . ) anastomotic stenosis serious system disease , include heart dysfunction , respiratory insufficiency , liver kidney dysfunction , serious blood disease participate clinical trial pregnancy perinatal woman combine malignant tumor history neurological psychiatric disorder patient abnormal bone marrow suppression chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>